Kanagawa, Japan

Hiroyuki Shimamura



Average Co-Inventor Count = 12.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2019

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Hiroyuki Shimamura: Innovator in Aminopyrazole Derivatives

Introduction

Hiroyuki Shimamura is a notable inventor based in Kanagawa, Japan. He has made significant contributions to the field of medicinal chemistry, particularly through his work on low-molecular-weight compounds that inhibit Src family kinases. His innovative approach has led to the development of valuable pharmaceutical compounds.

Latest Patents

Hiroyuki Shimamura holds 1 patent for his invention related to Aminopyrazole derivatives. The objective of this invention is to provide compounds that can effectively inhibit Src family kinases. The patent describes compounds represented by a general formula, which includes various substituted aryl and heteroaryl groups, along with pharmacologically acceptable salts.

Career Highlights

Throughout his career, Shimamura has worked with prominent companies in the pharmaceutical industry. He has been associated with Chugai Seiyaku Kabushiki Kaisha and F. Hoffmann-La Roche AG, where he has contributed to various research and development projects. His expertise in medicinal chemistry has been instrumental in advancing drug discovery efforts.

Collaborations

Hiroyuki Shimamura has collaborated with esteemed colleagues, including Hirosato Ebiike and Toshihiro Aoki. These collaborations have fostered a productive environment for innovation and have led to significant advancements in their respective fields.

Conclusion

Hiroyuki Shimamura's work in the development of Aminopyrazole derivatives showcases his commitment to advancing medicinal chemistry. His contributions have the potential to impact therapeutic strategies for various diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…